PT -期刊文章盟c Houillier AU - x王盟- g . Kaloshi AU - k Mokhtari称非盟- r . Guillevin AU - j . Laffaire AU - s巴黎AU - b . Boisselier AU - a . Idbaih盟- f . Laigle-Donadey AU - k . Hoang-Xuan AU - m .参盟J.-Y。Delattre TI - < em > IDH1 < / em >或< em > IDH2 < / em >突变预测更长生存和应对temozolomide低级神经胶质瘤援助- 10.1212 / WNL。0 b013e3181f96282 DP - 2010年10月26日TA -神首页经病学第六PG - 1560 - 1566 - 75 IP - 17 4099 - //www.ez-admanager.com/content/75/17/1560.short 4100 - //www.ez-admanager.com/content/75/17/1560.full所以Neurology2010 10月26日;75 AB -目标:最近的研究表明,经常IDH1和IDH2基因突变发生在神经胶质瘤,包括低级的神经胶质瘤。然而,它们对低级神经胶质瘤的预后和化学敏感性的影响尚不清楚。方法:搜索IDH1和IDH2基因突变,染色体杂合性丢失在1 p和19个,管理启动子甲基化,和p53表达了271年一系列的低级神经胶质瘤,与整体生存。接受治疗的84名病人建立一组预先替莫唑胺(抗肿瘤个性化。替莫唑胺(抗肿瘤反应评估无进展生存,以及肿瘤大小在连续的核磁共振扫描,然后与分子改变。结果:IDH IDH1或IDH2基因突变被发现在132/189(70%)的患者。IDH突变和1 p-19q codeletion与延长总生存期在单变量有关(p = 0.002, p = 0.0001)和多变量分析(p = 0.003, p = 0.004)。 1p-19q codeletion, MGMT promoter methylation, and IDH mutation (p = 0.01) were correlated with a higher rate of response to temozolomide. Further analysis of the course of the disease prior to any treatment except for surgery (untreated subgroup) showed that 1p-19q codeletion was associated with prolonged progression-free survival in univariate analysis, whereas IDH mutation was not. Conclusion: IDH mutation appears to be a significant marker of positive prognosis and chemosensitivity in low-grade gliomas, independently of 1p-19q codeletion, whereas its impact on the course of untreated tumors seems to be limited.